Sunshine Biopharma, Inc. SBFM
We take great care to ensure that the data presented and summarized in this overview for Sunshine Biopharma, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in SBFM
Top Purchases
Top Sells
About SBFM
Insider Transactions at SBFM
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 04
2024
|
Steve N. Slilaty Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
100,000
+43.48%
|
$0
$0.1 P/Share
|
|
Feb 08
2024
|
Steve N. Slilaty Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
20,000
+40.0%
|
$0
$0.1 P/Share
|
|
Nov 30
2022
|
Camille Sebaaly CFO/Secretary |
BUY
Open market or private purchase
|
Direct |
30,000
+14.67%
|
$0
$0.76 P/Share
|
Last 12 Months Summary
Buy / Acquisition
120K
Shares
From
1
Insiders
| Open market or private purchase | 120K shares |
|---|
Sell / Disposition
0
Shares
From
0
Insiders